Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.58 |
| ▸ | PHF8 | Q9UPP1 | 8/20 | 0.57 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.52 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.52 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17686545 | 0.90 | PHF8 (0.61) | KDM2BPHF8KDM4CKDM5BKDM4A | |
| SCHEMBL30589234 | 0.90 | PHF8 (0.61) | KDM2BPHF8KDM4CKDM5BKDM4A | |
| SCHEMBL17604579 | 0.89 | PHF8 (0.61) | KDM2BPHF8KDM4CKDM5BKDM4A | |
| SCHEMBL17693334 | 0.89 | PHF8 (0.58) | KDM2BPHF8KDM4CKDM5BKDM4A | |
| SCHEMBL30589230 | 0.89 | PHF8 (0.61) | KDM2BPHF8KDM4CKDM5BKDM4A | |
| SCHEMBL17686569 | 0.89 | PHF8 (0.57) | KDM2BPHF8KDM4CKDM5BKDM4A | |
| SCHEMBL30589240 | 0.89 | PHF8 (0.57) | KDM2BPHF8KDM4CKDM5BKDM4A | |
| SCHEMBL19383018 | 0.84 | KDM2B (0.69) | KDM2BPHF8KDM4CKDM5BKDM4A | |
| SCHEMBL19383415 | 0.82 | KDM5B (0.54) | KDM2BPHF8KDM4CKDM5BKDM5A | |
| SCHEMBL19383320 | 0.77 | PHF8 (0.73) | KDM2BPHF8KDM4CKDM5BKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436445-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3193881-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3436445-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10174003-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10071984-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2017161033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20170240529-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3193881-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9676770-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2016044342-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071984-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | KDM2B 15/4885PHF8 35/4885KDM4C 14/4885 |
| US-10174003-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | KDM2B 15/4885PHF8 35/4885KDM4C 14/4885 |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM2B 15/4885PHF8 35/4885KDM4C 14/4885 |
| US-20170240529-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM2B 15/4885PHF8 35/4885KDM4C 14/4885 |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM2B 15/4885PHF8 35/4885KDM4C 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.